Capricor Therapeutics price target raised to $40 from $18 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Capricor Therapeutics to $40 from $18 and keeps a Buy rating on the shares. The company is now well-funded beyond the expected regulatory milestones, the analyst tells investors in a research note. The firm believes Capricor’s recent updates provide “critical visibility” to both investors and potential additional partnerships beyond the already signed U.S. and Japan partnership with Nippon Shinyaku.